More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas.
At the annual ASTRO meeting, experts shared that not only did the shortened protocol shave weeks off of the scheduled treatment plan, it also did not come at the expense of increased toxicity.
When referring physicians agree with radiologists’ recommendations on the clinical necessity of follow-up imaging, three-quarters of patients go on to complete the additional exam.
Compared to a group of patients who had not been previously diagnosed with Lyme disease, those who had been infected displayed unusual activity in the frontal lobe of the brain on functional MRI scans.
“The findings of this study are important because they provide fresh evidence that the use of e-cigarettes could interfere with normal heart rhythms—something we did not know before,” according to one specialist.
After programming its EMR to automatically order ultrasound screenings for people at risk of abdominal aortic aneurysms (AAAs), a healthcare system saw a 540% spike in monthly screening exams for the condition over a six-year period.
